Aktie 300601 SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Shenzhen Kangtai Biological Products Co., Ltd.

Aktien

300601

CNE100002Q33

300601

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 25.04.2024 		% 5 Tage % 1. Jan.
19.39 CNY -0.62% Intraday Chart für Shenzhen Kangtai Biological Products Co., Ltd. -4.95% -28.58%
10.01. Kangtai Biological prognostiziert Rückkehr zum Gewinn im Jahr 2023 MT
2023 Shenzhen Kangtai Biological Products Co., Ltd. meldet Ergebnis für die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Kangtai Biological Forecasts Swing to Profit in 2023
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Shenzhen Kangtai Biological Products Co., Ltd. Announces Interim Profit Distribution Plan to Be Implemented (A Shares) for 2023, Payable on 13 October 2023
Shenzhen Kangtai Biological Products Co., Ltd. Approves 2023 Interim Cash Dividend
Kangtai Signs Deal to Distribute Varicella Vaccine in Pakistan, India
Shenzhen Kangtai Biological Products Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2023
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Kangtai Biological Partners With Indian Drugmaker to Distribute Pneumococcal Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.
Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback announced on October 12, 2022 has closed with 3,581,600 shares, representing 0.32% for CNY 120.97 million.
Shenzhen Kangtai Biological sees 2022 net loss on weaker COVID shot demand
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.
Shares in Chinese Pharma Companies Decline Amid Drop in Vaccination Rates
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.
Shenzhen Kangtai Biological Products Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on September 14, 2022.
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Shenzhen Kangtai Biological Products Co., Ltd. authorizes a Buyback Plan.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300601 Aktie
  4. Nachrichten Shenzhen Kangtai Biological Products Co., Ltd.
  5. Andere Sprachen